Investor Relations

 

Sales Recap:

During the three-month period ended September 30, 2011, product sales increased by 15%, or $130,000, to $1,003,000 in comparison to the same period in 2010.  During the nine-month period ended September 30, 2011, product sales increased by 17%, or $543,000, to $3,807,000 in comparison to the same period in 2010.  During the nine-month period ended September 30, 2011, sales of our animal health products (excluding sales of our water diagnostic reagents) increased by 22%.

 

“A 26% increase in sales of our lead product, First Defense®, during the first nine months of 2011 over the same period in 2010, demonstrates a solid return on our increased investment in sales and marketing,” commented Michael F. Brigham, President and CEO.  “During the third quarter of 2011, sales of First Defense® increased by 22% over the same period in 2010, representing the fourth consecutive quarter of double digit growth in sales of this product.” 

Financial Statements

eXtensible Business Reporting Language (XBRL)

XBRL is an XML-based language for the electronic transmission of business and financial data. XBRL is not an accounting standard; it is simply a standard for transmitting business and financial data.

The various XBRL exhibits included on this web page are displayed in their native XML format and have been included to provide you the option of importing them into your XBRL viewer of choice.

 

 

 

 

ImmuCell is a public biotechnology company that is developing, manufacturing and selling products that improve animal health and productivity in the dairy and beef industries. Our product focus encompasses prevention, diagnosis and treatment of economically important bovine diseases.

Contact
Investor Relations:
Michael F. Brigham
President & CEO
ImmuCell Corporation
56 Evergreen Drive
Portland, Maine 04103
207-878-2770
mbrigham@immucell.com

For up-to-date quotes:

• FlashQuote
• Yahoo Finance
• InfoQuote